Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11

Cancer Research

Volumn 59, Issue 24, 1999, Pages 6153-6158

  Gliniak, Brian ^a   Le, Tiep ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; IRINOTECAN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CAMPTOTHECIN; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HT29 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033572413     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C-P., Nicholl, J. K., Sutherland, G. R., Davis Smith, T., Rauch, C., Smith, C. A., and Goodwin, R. G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3: 673-682, 1995.
2. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. Induction of apoptosis by Apo-2 ligand. a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271: 12687-12690, 1996.
3. Griffith, T. S., and Lynch, D. H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol., 10: 559-563, 1998.
4. Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., and Kubin, M. Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol., 161: 2833-2840, 1998.
5. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C. T., Schuh, J. C. L., and Lynch, D. H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 5: 157-163, 1999.
6. Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K., and Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res., 59: 734-741, 1999.
7. Walczak, H., Degli-Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., Timour, M. S., Gerhart, M. J., Schooley, K. A., Smith, C. A., Goodwin, R. G., and Rauch, C. T. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J., 16: 5386-5397, 1997.
8. Wall, M. E., Wani, M. C., and Cook, C. E. Plant anti-tumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88: 3888-3890, 1966.
9. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T., and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep., 54: 461-470, 1970.
10. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
11. Hsiang, Y. H., and Liu, L. F. Identification of mammalian DNA topoisomerase 1 as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
12. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boué, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase 1 inhibitor 7-ethyl-10-(4-[l-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53: 2823-2829, 1993.
13. Houghlon, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
14. Guichard, S., Cussac, D., Hennebelle, L. Bugat, R., and Canal, P. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int. J. Cancer, 73: 729-734, 1997.
15. Jansen, W. J. M., Kolfschoten, G. M., Erkelens, C. A. M., Van Ark-Otte, J., Pinedo, H. M., and Boven, E. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. Int. J. Cancer, 73: 891-896, 1997.
16. Vassal, G., Boland, I., Santos, A., Bissery, M-C., Terrier-Lacombe, M-J., Morizet, J., Sainte-Rose, C., Lellouch-Tubiana, A., Kalifa, C. and Gouyette, A. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int. J. Cancer, 73: 156-163, 1997.
17. Jansen, W. J. M., Zwart, B., Hulscher, S. T. M., Giaccone, G., Pinedo, H. M., and Boven, E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int. J. Cancer, 70: 335-340, 1997.
18. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
19. Lavelle, F., Bissery, M. C., André, S., Roquet, F., and Riou, J. F. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin. Oncol., 23: 11-20, 1996.
20. Wu, G. S., Burns, T. F., McDonald, E. R., III, Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D-D., Zhou, J-Y., Muschel, R., Hamilton, S. R., Spinner, N. B., Markowitz, S., Wu, G., and El-Deiry, W. S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet., 17: 141-143, 1997.
21. Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and Dixit, V. M. The receptor for the cytotoxic ligand TRAIL. Science (Washington DC), 276: 111-113, 1997.
22. Pan, G., Ni, J., Wei, Y-F., Yu, G., Gentz, R., and Dixit, V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (Washington DC). 277: 815-818, 1997.
23. Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., and Goodwin, R. G. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 7: 813-820, 1997.
24. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature (Lond.), 364: 806-809, 1993.
25. Tanaka, M., Suda, T., Yatomi, T., Nakamura, N., and Nagata, S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol., 158: 2303-2309, 1997.
26. Havell, E. A., Fiers, W., and North, R. J. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med., 167: 1067-1085, 1988.
27. Shimada, Y., Rougier, P., and Pilot, H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur. J. Cancer. 32A (Suppl. 3): S13-S17, 1996.
28. Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., Bonneterre, J., Adenis, A., Seitz, J. F., Ganem, G., Namer, M., Conroy, T., Negrier, S., Merrouche, Y., Burki, F., Mousseau, M., Herait, P., and Mahjoubi, M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol., 15: 251-260, 1997.
29. Pitot, H. C., Wender, D. B., O'Connell, M. J., Schroeder, G., Goldberg, R. M., Rubin, J., Mailliard, J. A., Knost, J. A., Ghosh, C., Kirschling, R. J., Levitt, R., and Windschitl, H. E. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J. Clin. Oncol., 15: 2910-2919, 1997.